Recovery article

Thymosin beta-4 28-44, PLPSKETIEQEKQAGES, 1mg Epitope Peptide

Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES US$178.10 Excluding tax and shipping fees Limited stock Description About Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES The Human Thymosin beta-4 Peptide (IEDB: 554902) is a high quality epitope peptide for stimu

By Recovery & Performance Peptides Editorial Team Published July 27, 2026

Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

US$178.10

Excluding tax and shipping fees

Limited stock

Description

About Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

The Human Thymosin beta-4 Peptide (IEDB: 554902) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Thymosin beta-4 Peptide, H-PLPSKETIEQEKQAGES-OH (Uniprot: P62328 aa: 28-44) from JPT is produced under strict quality control and quality management.

Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES - Specifications

Peptide sequence: H-PLPSKETIEQEKQAGES-OH

Amount: 1 mg

Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)

Counterion: TFA

Delivery Format: Freeze-dried in plastic vial

Application(s): T-cell Immunity

Condition(s)/Topic(s): Arthritis

Standard Delivery Time: approx. 3 weeks

Your Custom or Scrambled Antigen Peptide!

Do you need a scrambled version of this antigen peptide?We can produce scrambled versions for all our antigen peptides and other peptide sequences. These scrambled peptide versions are cross-checked against the Uniprot database to ensure that the scrambled sequence does not correspond to any natural sequence. Have a look at Scrambled Antigen Peptides!

Are you interested in other antigen peptides?Choose sequence, amount and purity. We will assist you along the way: Custom Peptide Synthesis

JPT’s Antigen PeptidesFind your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides- All peptides are made in Germany- Bulk orders or custom peptide snythesis upon request- Synthesis protocols designed to avoid toxic contaminants and side products - Provision of freeze dried aliquots for enhanced stability - Proven track record for applications in clinical studies- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

References:Read References with Antigen Peptides

Documentation

Documentation for Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

Protocol_PepMix.pdf

Thymosin-beta-4-28-44-PLPSKETIEQEKQAGES-2.pdf

Properties

Properties of Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

T-cell immunity

Antigen Peptides

Arthritis

Freeze-dried in glass vial, Freeze-dried in plastic vial

Human

Thymosin beta-4

Trial Grade: each peptide purified to > 90% (HPLC/MS)

Further Information to Human Thymosin beta-4 28-44, PLPSKETIEQEKQAGES

Values

H-PLPSKETIEQEKQAGES-OH

17mer peptide as TFA salt

Post-session references

Selected from shared article topics. Source links are retained where available.

COACH'S BOARD / KEY POINTS

Regulatory Status: As of April 2026, thymosin beta-4 is not FDA-approved for any indication. RGN-259 (0.1% Tβ4 ophthalmic solution, developed by RegeneRx) has completed Phase II and Phase III trials for dry eye and neurotrophic keratopathy and holds orphan drug designation; no FDA approval has been granted. Available only through licensed compounding pharmacies by prescription.
Research Stage: Phase I safety data in healthy volunteers; Phase II and Phase III RCT data in ophthalmic disease; Phase I cardiac safety data; most recent human cardiac RCT published in 2025
Availability: Not available through Superpower. Access, where available, is through licensed 503A compounding pharmacies under a patient-specific prescription and varies by state.
Prescribing information: View compound reference data (PubChem CID 16133418)
How it works: Sequesters G-actin monomers, promoting cell migration, angiogenesis, and anti-inflammatory signaling after tissue injury.
What the research shows: In a 2022 Phase III randomized controlled trial published in International Journal of Molecular Sciences by Sosne and colleagues, RGN-259 significantly improved corneal healing and comfort in patients with neurotrophic keratopathy. A 2025 human RCT published in Cardiovascular Research by Zhang and colleagues evaluating recombinant human Tβ4 in 96 patients with acute ST-elevation myocardial infarction did not show a significant overall reduction in infarct size at 90 days, but identified a significant reduction in the subgroup treated within 8 hours of percutaneous coronary intervention.

SOURCE / superpower.com ↗

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

STORAGE

Storage Requirements

Lyophilized (powder) Room temperature or refrigerated, protect from light Reconstituted Refrigerated 36-46F (2-8C), use within 30 days

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Cardiomyocyte Protection Research: Ischaemia-Reperfusion and Apoptosis

Cardiac ischaemia-reperfusion (I/R) injury is the primary research context for Tβ4 cardiomyocyte protection. Primary neonatal rat ventricular myocytes (NRVM, P1-P3 rat hearts, collagenase II type II enzymatic dissociation, Percoll 40.5/58.5% gradient purification, plated 4×10⁵/cm² in 10% FBS DMEM/M199 4:1, beating monolayer confirmation at 48-72h) subjected to simulated ischaemia (SI/R: hypoxia 94%N₂/5%CO₂/1%O₂, glucose-free PBS, 60-90 min) → reoxygenation (normoxic complete medium, 120 min) with Tβ4 pre-treatment (10-1000 ng/mL, 24h before SI) or post-treatment (at reperfusion onset). Cardiomyocyte viability endpoints: LDH release (Promega CytoTox 96, OD490, % cytotoxicity); propidium iodide (PI) inclusion flow cytometry; ATP content (CellTiter-Glo, Promega, relative luminescence); JC-1 mitochondrial membrane potential (ΔΨm, 530 nm green monomer vs 590 nm red aggregate, depolarisation indicating apoptosis onset). Apoptosis endpoint cascade: cytochrome c (cytosolic ELISA or western), caspase-9 and caspase-3 activity (Caspase-Glo substrates), PARP cleavage western, and TUNEL (in situ cell death detection, Roche, fixed sections). Akt Ser-473 and ERK1/2 Thr-202/Tyr-204 phosphorylation western (Tβ4-ILK-PI3K-Akt and Tβ4-Akt-ERK MAPK survival cascades) with PI3K inhibitor LY294002 (10 μM) and MEK inhibitor PD98059 (10 μM) separating PI3K-Akt versus MAPK-ERK contributions to Tβ4 protection. In vivo MI model: C57BL/6 mouse left anterior descending (LAD) coronary artery ligation (permanent or 30-min occlusion-reperfusion), Tβ4 treatment by pericardial injection (1.6 mg/kg at time of surgery), i.p. injection (20-100 μg/mouse), or pre-treated slow-release subcutaneous pellet. Echocardiography (Vevo 2100 or 3100, 30 MHz transducer, M-mode and B-mode): LVEF (Simpson’s biplane method), FS (fractional shortening), LVEDD, LVESD, LV mass (Devereux formula) at baseline, 24h, 7d, 28d post-MI. TTC infarct sizing at 24h (% LV); cardiac troponin I (cTnI) plasma ELISA; histology: Masson trichrome (scar area % LV), α-SMA+ myofibroblast density (scar border zone), and CD31 neovessel density (border zone, vessels/mm²) at 7d and 28d.

RESEARCH

Thymosin Beta 4 (TB-500) and Related Research Studies

by Dr. Usman | Mar 30, 2022 | Research Thymosin Beta-4 has been documented by researchers to potentially play a role in protecting, regenerating, and remodeling damaged tissue cells. After any tissue injury, it is believed that Thymosin Beta-4 may be released by damaged cells to protect them and reduce the inflammatory process. This peptide is believed to be present in every tissue except red cells. Studies suggest that the first gene coding to occur (the process by which DNA and RNA dictate how and which cells need to form) after cell damage is Thymosin Beta-4. The formation of new blood vessels is believed to be essential to promote tissue repair. Damaged cells are believed to require early nutrients and supportive chemicals to reverse the damage. Thymosin Beta-4 is believed to have an angiogenic quality speculated to stimulate the migration and proliferation of endothelial cells.

POTENTIAL BENEFITS

Anti-Aging Benefits

TB-4’s regenerative properties extend to skin health as well. It can help reduce the appearance of fine lines and wrinkles, improve skin elasticity, and promote a youthful complexion.

Product & matchup locker

Linked catalog and comparison files.

Comparison

Related Comparisons & Guides

TB-4 Dosing Guide — Clinical and preclinical dosing protocols, reconstitution, and injection routes TB-4 Injury Recovery Guide — How TB-4 supports recovery from specific injury ty…